Harvard University spinout raises $10M to advance platelet bioreactor technology
By removing human donations from the platelet equation, Platelet BioGenesis hopes to create a more reliable supply.
Two new Series A rounds inject $72M into regenerative medicine and NASH
Two of the hottest fields in biopharma got another boost this week, with a $32 million Series A raised by a regenerative medicine startup and a separate $40 million in financing for the treatment of liver fibrosis and NASH.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Stem cell treatment trial blinded three women. What went wrong?
The analysis said that the consent forms signed by the women did not mention a clinical trial.
Sanford Health invests up to $20M in stem cell device company
One of the largest hospital networks in the U.S., Sanford Health, has committed up to $20 million to help progress InGeneron's adipose-derived stem cell program.
Nine months of rheumatoid arthritis suppression with one stem cell dose?
Rheumatoid arthritis patients given a single intravenous dose of Mesoblast's novel stem cell therapy were still demonstrating therapeutic benefits nine months later, according to new Phase 2 data from the Melbourne, Australia-based company.
Stem cell startup Magenta launches with $48.5m
Atlas and Third Rock Ventures have co-led a $48.5 million Series A for Magenta, a Boston start-up hoping to revive the stem cell field with its novel transplant platform.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Regenerative medicine can rejuvenate healthcare
Self-regeneration designed to harness the body’s inherent power to heal itself is already improving lives and changing medical practices in many parts of the world.
Standing on the shoulders of stem cell gene therapists
With a switch from T cells to stem cells and a roller-coaster hype ride, the gene therapy field has delivered on its promise from over 25 years ago with a medicine that now offers a real hope for children with ADA-SCID.
Stem cell tourism goes domestic
The U.S. has 351 stem cell clinics making an awful lot of businesses making marketing claims about stem cell interventions,” said Leigh Turner, coauthor of the study and a bioethicist at University of Minnesota.
Small-molecule tool could reduce leukemia cell regeneration
“We showed that cancer stem cells co-opt an RNA editing system to clone themselves. What’s more, we found a method to dial it down,” said principal investigator Dr. Catriona Jamieson, of UC San Diego School of Medicine.
Maximize Revenue and Patient Care with Strategic Weight Loss Management
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Stem cells and biomechanics help predict and treat inherited heart defects
The technology, developed by a multi-institutional team led by the Cincinnati Children's Heart Institute, would allow doctors to intervene earlier to help patients manage their conditions and help inform future pharmacologic treatment options.
5AM Ventures launching stealth (RNA?) startup Homology Medicines with $23M
Its core science comes from Harvard Stem Cell Institute researcher Richard Gregory, who focuses on the function of miRNA in disease manifestation. We're guessing Homology Medicines is in this field as well.
Neurona gets $23.5M for stem cell approach to neurological disease
As opposed to taking a small molecule or even antibody approach to treating neurological disease, Neurona "is focused on unique compositions of cells that can be precisely targeted, integrated into damaged neural circuits, and provide activity-dependent regulation."
Peter Thiel-backed ‘unicorn’ biotech posits that stem cells are root cause of cancer
Stem CentRx posits that cancer is caused by stem cells gone awry - and is developing antibody drug conjugate therapies to help attack cancer at its root. The Peter Thiel-backed "unicorn" startup is valued at some $3 billion.
CardioCell developing stem cell therapy for chronic heart failure
CardioCell's in Phase 2a trials with its stem cell therapy for chronic heart failure. Its approach is to infuse stem cells into a patient's system taht stimulate the heart cells into to working again.